Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cti Biopharm Corp (CTIC)

Cti Biopharm Corp (CTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cti Biopharm Corp 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 USA

P: 206-282-7100 F: 206-284-6206

Description:

CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington.

Key Statistics

Overview:

Market Capitalization, $K 81,787
Shares Outstanding, K 73,682
Annual Sales, $ 3,350 K
Annual Net Income, $ -40,020 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -8,190 K
60-Month Beta 1.50
% of Insider Shareholders 3.90%
% of Institutional Shareholders 49.71%
Float, K 70,808
% Float 96.10%

Growth:

1-Year Return 33.92%
3-Year Return -66.57%
5-Year Return -94.61%
5-Year Revenue Growth -94.42%
5-Year Earnings Growth 89.38%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/07/20
Earnings Per Share ttm -0.69
EPS Growth vs. Prev Qtr -42.86%
EPS Growth vs. Prev Year -5.26%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-10 on 01/03/17

CTIC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -3.65
Price/Earnings to Growth N/A
Return-on-Equity % -163.14%
Return-on-Assets % -63.90%
Profit Margin % -1,194.63
Net Margin % N/A
Debt/Equity 0.25
Price/Sales 26.21
Price/Cash Flow N/A
Price/Book 3.92
Book Value/Share 0.31
Interest Coverage -39.02
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar